title: Dyslipidaemia, hypercoagulability and the metabolic syndrome.
abstract: The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability.
authors.affiliation: Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UK. MIKHAILIDIS@aol.com.
authors.forename: Anna I
authors.initials: AI
authors.lastname: Kakafika
authors.forename: Evagelos N
authors.initials: EN
authors.lastname: Liberopoulos
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D050154:Adiposity; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D002995:Clofibric Acid / Q000627:therapeutic use; D050171:Dyslipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D005167:Factor VII / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000378:metabolism; D007333:Insulin Resistance; D008019:Life Style; D008077:Lipoproteins, LDL / Q000097:blood; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000378:metabolism; D019851:Thrombophilia / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D018836:Inflammation Mediators; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D014280:Triglycerides; D014841:von Willebrand Factor; D002995:Clofibric Acid; D005167:Factor VII; D001241:Aspirin